<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998127</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1196</org_study_id>
    <secondary_id>09-367</secondary_id>
    <secondary_id>09-0421-F2L</secondary_id>
    <secondary_id>717/DG</secondary_id>
    <secondary_id>AAAE0348</secondary_id>
    <nct_id>NCT00998127</nct_id>
  </id_info>
  <brief_title>Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients</brief_title>
  <acronym>PARIS</acronym>
  <official_title>Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational research study is to determine when and why patients
      discontinue, interrupt, or disrupt the regimen of anti-platelet medications prescribed
      following stent implantation, and to examine the relationship between specific patterns of
      non-adherence and patient outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-platelet medicines are the cornerstone of therapy in patients who present with acute
      coronary syndromes, including unstable angina, non-ST elevation myocardial infarction
      (NSTEMI), and ST elevation myocardial infarction (STEMI). Multiple clinical trials have
      demonstrated the efficacy of dual anti-platelet therapy (DAPT) for the prevention of
      thrombotic events in patients who present with unstable coronary symptoms; in particular,
      patients who are to receive percutaneous coronary intervention (PCI). Dual anti-platelet
      therapy consists of a combination of aspirin and a thienopyridine (such as clopidogrel or
      ticlopidine). While premature discontinuation (within the first 6 months) of such therapy is
      associated with an increased risk of stent thrombosis, the optimal duration of DAPT has not
      yet been precisely determined.

      Although studies suggest an increased risk of stent thrombosis and adverse events within days
      after thienopyridine discontinuation, no study has collected detailed data as to the exact
      dates and reasons that anti-platelet agents were discontinued - thus, the true risks of
      premature early or even scheduled late discontinuation are unknown.

      Furthermore, there are multiple modes that impact subject adherence to DAPT. These include
      non-compliance and cost issues.

      We have determined three modes why subjects may not adhere to DAPT. These include:

        -  Discontinuation - These subjects have discontinued the use of DAPT (aspirin or
           thienopyridines) as per recommendation of their physician who has felt that the subject
           no longer needs this therapy.

        -  Interruption - These subjects have interrupted their DAPT use on a voluntary basis and
           under the guidance and recommendation of their physician due to the need for a surgical
           procedure, and will reinstitute the use of DAPT within 14 days of stopping the therapy.
           Interruptions must be guided by the physician/cardiologist taking care of the subject
           and not by other health care professionals.

        -  Disruption - These subjects have disrupted their DAPT use, either because of a bleeding
           episode (minor or major) or non-compliance. Non-compliance will include continued use of
           DAPT at lower dose levels than prescribed either through smaller daily doses or less
           frequent than daily use.

      These modes have not previously been systematically collected and correlated with adverse
      clinical events such as stent thrombosis. Furthermore, the relation of events to subsequent
      disruption of DAPT has not been studied prospectively. Subjects enrolled in this registry
      will be followed for approximately 24 months to determine the incidence of adherence
      according to the above classification. All patients will have their events and DAPT use
      monitored during the follow-up period. The assumption is that most subjects will discontinue
      their therapy voluntarily (usually according to their physician's advice) and that it is only
      those with disrupted therapy who are at risk for major adverse cardiac events (MACE). This
      registry will examine the predictors of DAPT disruption based on subject's demographics and
      determine the relationship of bleeding versus MI in these subjects using a time-dependent
      covariate adjusted analysis. Finally, since there are two completely different categories
      within the disrupted group, (non-compliance vs. event driven disruption), we will examine
      these patients separately as well, as a secondary endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Anti-platelet agent discontinuation/ interruption/ disruption</measure>
    <time_frame>at 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Anti-platelet agent discontinuation/ interruption/ disruption</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Anti-platelet agent discontinuation/ interruption/ disruption</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Anti-platelet agent discontinuation/ interruption/ disruption</measure>
    <time_frame>at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of major and minor bleeding (according to TIMI and ACUITY definitions)</measure>
    <time_frame>at 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of major and minor bleeding (according to TIMI and ACUITY definitions)</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of major and minor bleeding (according to TIMI and ACUITY definitions)</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of major and minor bleeding (according to TIMI and ACUITY definitions)</measure>
    <time_frame>at 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of definite and/or probable stent thrombosis (ARC definition)</measure>
    <time_frame>at 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of definite and/or probable stent thrombosis (ARC definition)</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of definite and/or probable stent thrombosis (ARC definition)</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of definite and/or probable stent thrombosis (ARC definition)</measure>
    <time_frame>at 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE. (MACE is defined as the composite of cardiac death, Q-wave myocardial infarction (MI), and unscheduled, ischemia driven revascularization of the target lesion.)</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE. (MACE is defined as the composite of cardiac death, Q-wave myocardial infarction (MI), and unscheduled, ischemia driven revascularization of the target lesion.)</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE. (MACE is defined as the composite of cardiac death, Q-wave myocardial infarction (MI), and unscheduled, ischemia driven revascularization of the target lesion.)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE. (MACE is defined as the composite of cardiac death, Q-wave myocardial infarction (MI), and unscheduled, ischemia driven revascularization of the target lesion.)</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of NACE (NACE is defined as the composite of cardiac death, MI (Q and non-Q-wave), ischemia driven revascularization of the target lesion and major bleeding (ACUITY criteria).)</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of NACE (NACE is defined as the composite of cardiac death, MI (Q and non-Q-wave), ischemia driven revascularization of the target lesion and major bleeding (ACUITY criteria).)</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of NACE (NACE is defined as the composite of cardiac death, MI (Q and non-Q-wave), ischemia driven revascularization of the target lesion and major bleeding (ACUITY criteria).)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of NACE (NACE is defined as the composite of cardiac death, MI (Q and non-Q-wave), ischemia driven revascularization of the target lesion and major bleeding (ACUITY criteria).)</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">5031</enrollment>
  <condition>Medication Non-adherence</condition>
  <condition>Stent Thrombosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects in any of the participating US or European sites who have undergone successful
        stent implantation in a native coronary artery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has been informed of the nature of the study, agrees to its provisions,
             and has signed and been provided an &quot;Informed Consent Form&quot; approved by the
             appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB).

          -  The subject must be â‰¥18 of age (or minimum age as required by local regulations) at
             the time of enrollment with successful stent placement in one or more lesions in
             native coronary arteries using an approved coronary stent.

          -  Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV), OR unstable angina pectoris (Braunwald
             Classification B&amp;C, I-II-III), OR subjects with documented silent ischemia, OR acute
             myocardial infarction.

          -  The subject is willing and able to cooperate with the study procedures and required
             follow-ups.

        Exclusion Criteria:

          -  Subjects with hypersensitivity or allergies to anti-platelet therapy.

          -  Subjects in whom anti-platelet and/or anticoagulation therapy is contraindicated.

          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following the index procedure.

          -  The subject is participating in an investigational device or drug study. Subject must
             have completed the follow-up phase of any previous study at least 30 days prior to
             enrollment in this study.

          -  Subject has a history of bleeding diathesis or coagulopathy.

          -  Subject has other medical illness (e.g., cancer, known malignancy or congestive heart
             failure) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may
             cause non-compliance with the followups as defined by the protocol or confound the
             data interpretation.

          -  Evidence of stent thrombosis by visual angiographic assessment during the index
             procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roxana Mehran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Colombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Raffaele Hospital (Milan, Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's/ Mid-America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBauer Cardiovascular Research Foundation</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onassis Cardiac Surgery Center</name>
      <address>
        <city>Athens</city>
        <zip>176 74</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dual Anti-Platelet Therapy</keyword>
  <keyword>Non-adherence</keyword>
  <keyword>MACE</keyword>
  <keyword>NACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

